Therefore, herbal combinational medication of GG and AR (100 mg/kg) have a potential to be developed into therapeutics for the treatment of COPD by regulating CXCL2/IL-17 production via modulation of the STAT3 pathway. This evidence concerns the gene CXCL2 and chronic obstructive pulmonary disease.